You are here Home Resources and guidance Sponsors PTC Therapeutics Australia Pty Ltd Regulatory activities for this sponsor. Listen Print Share LinkedIn (Twitter) Facebook Email Loading... Type Australian public assessment report (AusPar) (1) Designation or determination (1) Date 2025 (1) 2021 (1) Search Sponsor content2 result(s) found, displaying 1 to 2 Sephience 4 December 2025 Australian public assessment report (AusPar) Sephience (sepiapterin) has been approved for the treatment of hyperphenylalaninaemia in adult and paediatric patients with phenylketonuria. Notice for ataluren (PTC Therapeutics Australia Pty Ltd) 9 March 2021 Designation or determination Orphan drug
Sephience 4 December 2025 Australian public assessment report (AusPar) Sephience (sepiapterin) has been approved for the treatment of hyperphenylalaninaemia in adult and paediatric patients with phenylketonuria.
Notice for ataluren (PTC Therapeutics Australia Pty Ltd) 9 March 2021 Designation or determination Orphan drug